Kyowa Kirin will file for rocatinlimab’s US approval, which was once Amgen’s most late-stage pipeline candidate.
It may be known for its trends, but K-beauty's skin care philosophy is timeless.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results